TITLE

Prognostic value of proliferation markers expression in breast cancer

AUTHOR(S)
Dedić Plavetić, Natalija; Jakić-Razumović, Jasminka; Kulić, Ana; Vrbanec, Damir
PUB. DATE
June 2013
SOURCE
Medical Oncology;Jun2013, Vol. 30 Issue 2, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
87820163

 

Related Articles

  • Proliferation is the strongest prognosticator in node-negative breast cancer: significance, error sources, alternatives and comparison with molecular prognostic markers. Baak, Jan; Gudlaugsson, Einar; Skaland, Ivar; Guo, Lydia; Klos, Jan; Lende, Tone; Søiland, Håvard; Janssen, Emiel; Hausen, Axel // Breast Cancer Research & Treatment;Jun2009, Vol. 115 Issue 2, p241 

    Independent studies have shown that in node negative breast cancer patients less than 71 years, the proliferation marker mitotic activity index (MAI) is the strongest, most well reproducible prognosticator and chemotherapy success predictor. The MAI overshadows the prognostic value of tubule...

  • Aurora kinase A outperforms Ki67 as a prognostic marker in ER-positive breast cancer. Ali, H R; Dawson, S-J; Blows, F M; Provenzano, E; Pharoah, P D; Caldas, C // British Journal of Cancer;5/22/2012, Vol. 106 Issue 11, p1798 

    Background:Proliferation has emerged as a major prognostic factor in luminal breast cancer. The immunohistochemical (IHC) proliferation marker Ki67 has been most extensively investigated but has not gained widespread clinical acceptance.Methods:We have conducted a head-to-head comparison of a...

  • A clinically relevant gene signature in triple negative and basal-like breast cancer.  // Breast Cancer Research;2011, Vol. 13 Issue 4, p3035 

    The article offers information on the study conducted by the authors related to a clinically relevant gene signature in triple negative and basal-like breast cancer (TNBC). It states that current prognostic gene expression profiles for breast cancer mainly reflect proliferation status and are...

  • Increased expression of TMED2 is an unfavorable prognostic factor in patients with breast cancer. Lin, Xia; Liu, Jian; Hu, Shu Fang; Hu, Xun // Cancer Management & Research;Mar2019, Vol. 11, p2203 

    Background: We obtained 2 types of clones which were termed SC (sphere-shaped clone) and NSC (non-sphere-shaped clone) from 4T1 cells by monoclonal culture. SC and NSC were distinct in morphology, surface marker, metabolism and proliferation rate. With the transcriptome sequencing data analysis,...

  • Proliferation marker securin identifies favourable outcome in invasive ductal breast cancer. Talvinen, K; Tuikkala, J; Nevalainen, O; Rantanen, A; Hirsimäki, P; Sundström, J; Kronqvist, P // British Journal of Cancer;7/22/2008, Vol. 99 Issue 2, p335 

    We introduce a new proliferation marker, securin (pituitary tumour-transforming 1 (PTTG1)), analysed in invasive ductal breast carcinomas by cDNA microarrays and immunohistochemistry. In cDNA microarray of a total of 4000 probes of genes, securin was revealed with a significant change in...

  • ID2 predicts poor prognosis in breast cancer, especially in triple-negative breast cancer, and inhibits E-cadherin expression. Kai Li; Ling Yao; Li Chen; Zhi-Gang Cao; San-Jian Yu; Xia-Ying Kuang; Xin Hu; Zhi-Ming Shao // OncoTargets & Therapy;2014, Vol. 7, p1083 

    Background: Inhibitors of DNA-binding (ID) proteins are known as important modulators in the regulation of cell proliferation and differentiation. This study sought to investigate the prognostic value of ID proteins in breast cancer. Methods: The prognostic role of ID proteins in human breast...

  • The potential utility of geminin as a predictive biomarker in breast cancer. Sundara Rajan, Sreekumar; Hanby, Andrew; Horgan, Kieran; Thygesen, Helene; Speirs, Valerie // Breast Cancer Research & Treatment;Jan2014, Vol. 143 Issue 1, p91 

    Compared with other markers of cell proliferation, geminin is unique being expressed selectively during the proliferative phase of the cell cycle, specifically S, G2 and early mitosis, disappearing completely at the metaphase-anaphase transition. We aimed to compare the prognostic significance...

  • Clinicopathological significance of decreased galectin-3 expression and the long-term prognosis in patients with breast cancer. Yamaki, Sayaka; Fujii, Takaaki; Yajima, Reina; Hirakata, Tomoko; Yamaguchi, Satoru; Fujisawa, Tomomi; Tsutsumi, Soichi; Asao, Takayuki; Yanagita, Yasuhiro; Iijima, Misa; Kuwano, Hiroyuki // Surgery Today;Aug2013, Vol. 43 Issue 8, p901 

    Purpose: Galectin-3 expression is modulated in cancer cells, and that finding has led to the recognition of galectin-3 as a diagnostic or prognostic marker for various cancers, including breast cancer. This study investigated the correlation between galectin-3 expression and the...

  • Validity of the proliferation markers Ki67, TOP2A, and RacGAP1 in molecular subgroups of breast cancer. Milde-Langosch, Karin; Karn, Thomas; Müller, Volkmar; Witzel, Isabell; Rody, Achim; Schmidt, Markus; Wirtz, Ralph // Breast Cancer Research & Treatment;Jan2013, Vol. 137 Issue 1, p57 

    High proliferation rates are characteristic of cancer, and proliferation markers make up the majority of genes included in RNA-based prognostic gene signatures applied for breast cancer patients. Based on prior data on differences in molecular subgroups of breast cancer, we hypothesized that the...

  • Prognostic value of proliferation assay in the luminal, HER2-positive, and triple-negative biologic classes of breast cancer.  // Breast Cancer Research;2012, Vol. 14 Issue 1, pR3 

    The article informs about a study which aims at assessing the prognostic value of a proliferation assay by using Ki-67 immunohistochemistry as compared with mitotic count scores. It states that the recent gene-expression profiling studies have reemphasized its biologic and prognostic value. It...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics